tiprankstipranks
Sab Biotherapeutics, Inc. (SABS)
:SABS
US Market

SAB Biotherapeutics (SABS) Income Statement

Compare
139 Followers

SAB Biotherapeutics Income Statement

Last quarter (Q3 2024), SAB Biotherapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, SAB Biotherapeutics's net income was $-10.35M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 2.24M$ 23.90M$ 60.88M$ 55.24M$ 3.44M
Gross Profit
$ -1.51M$ 20.61M$ 59.22M$ 55.24M$ 3.44M
Operating Expenses
$ 36.57M$ 28.92M$ 13.39M$ 34.68M$ 12.12M
Depreciation and Amortization
$ 3.75M$ 3.29M$ 1.65M$ 548.18K$ 323.41K
EBITDA
$ -38.13M$ -15.12M$ -15.20M$ 21.14M$ -8.23M
Operating Income
$ -38.08M$ -28.92M$ -13.39M$ 20.56M$ -8.67M
Other Income/Expenses
$ -4.12M$ 10.20M$ -3.75M$ -439.02K$ -312.75K
Pretax Income
$ -42.19M$ -18.72M$ -17.14M$ 20.12M$ -8.99M
Net Income
$ -42.19M$ -18.74M$ -17.44M$ 20.12M$ -9.42M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -7.64$ -4.31$ -6.38$ 7.92$ -0.22
Diluted EPS
$ -7.64$ -4.31$ -6.38$ 7.45$ -0.22
Weighted Average Shares Outstanding
5.52M 4.35M 2.73M 2.54M 43.47M
Weighted Average Shares Outstanding (Diluted)
5.52M 4.35M 2.73M 2.70M 43.47M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis